Monopar Therapeutics Inc. (NASDAQ:MNPR) Major Shareholder Tactic Pharma Llc Sells 33,334 Shares

Monopar Therapeutics Inc. (NASDAQ:MNPR) major shareholder Tactic Pharma Llc sold 33,334 shares of the business’s stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $35.00, for a total value of $1,166,690.00. Following the transaction, the insider now owns 822,255 shares of the company’s stock, valued at $28,778,925. The trade was a 3.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Monopar Therapeutics Price Performance

Shares of MNPR opened at $30.00 on Friday. The firm has a 50-day moving average of $38.29 and a 200-day moving average of $24.88. The company has a market cap of $183.39 million, a PE ratio of -15.23 and a beta of 1.01. Monopar Therapeutics Inc. has a one year low of $1.72 and a one year high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings results on Monday, March 31st. The company reported ($2.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($1.87). Analysts expect that Monopar Therapeutics Inc. will post -1.65 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on MNPR. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Monopar Therapeutics in a report on Tuesday. Piper Sandler reiterated an “overweight” rating and set a $76.00 price objective on shares of Monopar Therapeutics in a report on Wednesday, March 19th. Finally, Jones Trading reissued a “hold” rating on shares of Monopar Therapeutics in a research note on Wednesday. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.00.

Institutional Trading of Monopar Therapeutics

Several hedge funds have recently added to or reduced their stakes in MNPR. JPMorgan Chase & Co. bought a new position in Monopar Therapeutics during the 4th quarter worth $45,000. Geode Capital Management LLC grew its stake in Monopar Therapeutics by 174.4% during the fourth quarter. Geode Capital Management LLC now owns 38,596 shares of the company’s stock worth $849,000 after buying an additional 24,530 shares in the last quarter. ADAR1 Capital Management LLC bought a new position in Monopar Therapeutics in the 4th quarter valued at about $2,861,000. Point72 Asset Management L.P. acquired a new position in shares of Monopar Therapeutics in the 4th quarter valued at approximately $3,694,000. Finally, RA Capital Management L.P. bought a new stake in Monopar Therapeutics during the fourth quarter worth $11,247,000. 1.83% of the stock is owned by institutional investors and hedge funds.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.